Codetta Bio specializes in advanced biomarker measurement technologies that leverage a multi-omics approach for precision medicine. Their platform integrates digital PCR and qPCR methodologies to provide comprehensive analysis of blood-based protein biomarkers. This innovative system allows for the rapid and sensitive detection of DNA, RNA, and proteins from a single sample, significantly reducing analysis time from two days to just two hours. The Codetta Bio Platform is designed to streamline laboratory workflows by consolidating multiple instruments into one multifunctional solution, thereby enhancing efficiency and reducing operational costs.

The company's unique trifecta of capabilities includes ultra-sensitive detection of low target proteins and nucleic acids, quantification of high target concentrations, and the application of "noise-canceling technology" to eliminate background signals in multiplex assays. This combination not only improves the sensitivity of biomarker measurements but also facilitates better decision-making in clinical trials by providing critical insights into disease progression and therapy response. Codetta Bio's integrated platform aims to redefine the standards of capability in mid-plex translational research and clinical markets, ultimately accelerating the path to clinical success.

United States

Codetta Bio is a company developing an integrated platform for highly multiplexed, quantitative, simultaneous multi-omic analyses of nucleic acid and protein assays. They are focused on precision medicine and accelerating clinical success through their advanced multi-omic biomarker measurement tools.

Codetta Bio

Company Details